Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6672350 | 0.90 | TTR (0.60) | KMT2AMEN1TTRMAPK1KDM4E | |
| SCHEMBL5387584 | 0.90 | TTR (0.65) | KMT2AMEN1TTRMAPTKDM4E | |
| Phosphine SCHEMBL4434544 | 0.89 | TTR (0.59) | KMT2AMEN1TTRMAPK1KDM4E | |
| SCHEMBL11093699 | 0.89 | TTR (0.59) | KMT2AMEN1TTRMAPK1KDM4E | |
| SCHEMBL6745677 | 0.88 | BCHE (0.48) | SLC2A1KMT2AMEN1ATMTTR | |
| SCHEMBL6743221 | 0.87 | C5AR1 (0.49) | SLC2A1KMT2AMEN1ATMMAPK1 | |
| SCHEMBL1027720 | 0.86 | PDE4B (0.43) | SLC2A1KMT2AMEN1ATMTTR | |
| SCHEMBL6739512 | 0.86 | PDE4B (0.43) | SLC2A1KMT2AMEN1ATMTTR | |
| SCHEMBL13448207 | 0.85 | SLC2A1 (0.52) | SLC2A1KMT2AMEN1ATMTTR | |
| SCHEMBL10852995 | 0.84 | FFAR4 (0.62) | TTRMAPK1MAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612598-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-03-28 | — | — | US | disclosed |
| EP-1893210-B1 | SELECTIVE APOPTOTIC INDUCTION IN CANCER CELLS INCLUDING ACTIVATION OF PROCASPASE-3 | UNIV ILLINOIS (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-07-04 | — | — | US | disclosed |
| US-10166229-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180360824-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-12-20 | — | — | US | disclosed |
| US-10022371-B2 | Procaspase-activating compounds and methods | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022371-B2 | Procaspase-activating compounds and methods | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-07-17 | — | — | US | disclosed |
| EP-2753333-B1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED INC (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2753333-B1 | CAFFEINATED COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES | PROTAMED INC (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9663482-B2 | Substituted piperazinyl acetohydrazide procaspase-activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-30 | — | — | US | disclosed |
| US-5807837-A | ADMINISTERING TO TREAT HIV INFECTIONS TO INHIBIT THE REPLICATION OF FOREIGN NUCLEIC ACIDS IN A NORMAL CELL | SANKYO COMPANY, LIMITED (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0858999-A1 | Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5674856-A | TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS, INCLUDING AIDS AND TUMORS | SANKYO COMPANY, LIMITED (JP) | 1997-10-07 | — | — | US | disclosed |
| US-5610294-A | VIRAL TREATMENT | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| EP-0611075-B1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO CO (JP) | 1996-12-18 | — | — | EP | disclosed |
| EP-0703218-A1 | Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
| WO-1996005828-A1 | PYRROLIDINYL DI-CARBOXYLIC ACID DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-02-29 | — | — | WO | disclosed |
| EP-0611075-A1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-4012389-A | ANTICOAGULANTS | DONAU-PHARMAZIE GESELLSCHAFT M.B.H. (OE) | 1977-03-15 | — | — | US | disclosed |
| US-3935214-A | ANTICOAGULANT | DONAU-PHARMAZIE GESELLSCHAFT M.B.H. (OE) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10166229-B2 | Compounds and methods for the treatment of cancer | CASP3, CASP6, CASP5 | SLC2A1 4753/4885KMT2A 1515/4885MEN1 3608/4885 |
| US-20180360824-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS | CASP3, CASP5, CASP6 | SLC2A1 4416/4885KMT2A 3185/4885MEN1 3281/4885 |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | CASP3, BAX, CASP6 | SLC2A1 4241/4885KMT2A 3132/4885MEN1 3135/4885 |
| US-11612598-B2 | Compounds and methods for the treatment of cancer | CASP3, BAX, CASP6 | SLC2A1 4241/4885KMT2A 3132/4885MEN1 3135/4885 |
| US-10022371-B2 | Procaspase-activating compounds and methods | CASP3, CASP5, CASP6 | SLC2A1 4416/4885KMT2A 3185/4885MEN1 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.